The US venture Bellicum Pharmaceuticals Inc. has reached a deal with Astellas Pharma Inc.'s US-based R&D operation Agensys Inc. under which Bellicum will license in certain technology relating to prostate stem cell antigen (PSCA) for use in potential immuno-oncology therapies.
Bellicum Deal Enables Astellas To Progress PSCA Tech
Bellicum has licensed in global rights to apply certain technology from Astellas to PSCA-targeting cell therapies for cancer, in a deal which helps the US firm take its first candidate in the field into the clinic next year, and enables Astellas to benefit from an area where it had previously discontinued some of its own projects.
More from Japan
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
Move to acquire profitable Tokyo-based venture part of Japanese major's strategy of building a broader ecosystem for dementia detection and care.
• By
With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.
More from Focus On Asia
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.